Grant Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Sep. 01, 2022	Jan. 13, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities			$ 489,090	$ 236,512
Other Current Assets			26,400
Grant Member
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants			35,325	8,347	$ 9,123
National Institutes of Health | Grant Member
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants			26,400
Human Immunodeficiency Virus ("HIV") Grant | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant awarded amount. maximum			55,700
Vaccinal Antibody Grant [Member] | Grant Member
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants			8,600	8,200	$ 8,600
Vaccinal Antibody Grant [Member] | Bill & Melinda Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common Stock, Shares Purchased		881,365
Common Stock, Shares Purchased, Share Price		$ 45.38
Common Stock, Shares Purchased , Aggregate Purchase Price		$ 40,000
Common stock, shares issued, fair market value		$ 28,500
Closing stock price		$ 37.65
Underlying shares, Premium received		$ 11,300
Accrued and other liabilities			7,700	1,800
Transaction Price Upon Option Exercise			$ 15,500	$ 6,800
BARDA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential maximum amount of grant	$ 1,000,000
Maximum amount of grant during the base period	$ 55,000